Education
About Us
Working with TipRanks
Follow Us
Balchem Corp. (BCPC)
NASDAQ:BCPC
BCPC Stock Chart & Stats
$182.66
$0.69(0.44%)
At close: 4:00 PM EST
$182.66
$0.69(0.44%)
Day’s Range― - ―
52-Week Range$139.17 - $183.90
Previous CloseN/A
Volume32.16K
Average Volume (3M)168.70K
Market Cap
$5.63B
Enterprise Value$5.81B
Total Cash (Recent Filing)$74.57M
Total Debt (Recent Filing)$192.01M
Price to Earnings (P/E)32.3
Beta0.47
Next Earnings
Apr 24, 2026EPS Estimate
1.25Next Dividend Ex-DateN/A
Dividend Yield0.61%
Share Statistics
EPS (TTM)1.21
Shares Outstanding32,025,390
10 Day Avg. Volume186,796
30 Day Avg. Volume168,697
Financial Highlights & Ratios
PEG Ratio1.54
Price to Book (P/B)3.98
Price to Sales (P/S)4.82
P/FCF Ratio23.09
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue5.60
Enterprise Value/Gross Profit15.67
Enterprise Value/Ebitda21.89
Forecast
1Y Price Target
$190.00Price Target Upside4.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)5.13
Revenue Forecast (FY)$1.10B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & FCF ImprovementRobust cash conversion (OCF > net income and FCF up ~34% in 2025) provides durable funding for capex, dividends, buybacks and M&A. Reliable cash flow enhances financial flexibility and resilience across cycles, supporting execution of long-term strategic initiatives despite past FCF volatility.
Very Conservative Balance SheetExtremely low leverage and a strengthened equity base give Balchem persistent optionality to invest organically, pursue acquisitions, or sustain shareholder returns without stressing liquidity. Conservative balance sheet materially reduces refinancing and solvency risks over a multi‑quarter horizon.
Diversified Growth Platforms And R&D PipelineMultiple revenue engines (Human Nutrition, Animal Nutrition, Specialty Products) plus 20+ clinical studies, strategic marketing partnerships and a new microencapsulation facility create differentiated products and adoption channels. This innovation-driven diversification supports sustainable market share gains and long-term organic growth.
Bears Say
Input-cost Pressure On Gross MarginsRising manufacturing input costs reduced gross margin by ~40 basis points in Q4. If input inflation persists or pricing pass-through is constrained, margin expansion could stall, limiting operating profit and free cash flow growth and pressuring long-term profitability targets.
Tariff And Regulatory UncertaintyRegulatory shifts around tariffs create planning and cost uncertainty; management cites a remaining potential exposure (~$10M). Evolving duties or refunds can change competitive dynamics and supply‑chain economics, complicating pricing, forecasting and margin stability over the medium term.
Dependence On Clinical Study OutcomesCommercial claims and some growth initiatives hinge on positive clinical results and publications. Adverse, inconclusive or delayed study outcomes would constrain marketing claims and adoption, turning expected product-driven revenue upside into a contingent, execution‑sensitive risk over multiple quarters or years.
Balchem News
BCPC FAQ
What was Balchem Corp.’s price range in the past 12 months?
Balchem Corp. lowest stock price was $139.17 and its highest was $183.90 in the past 12 months.
What is Balchem Corp.’s market cap?
Balchem Corp.’s market cap is $5.63B.
When is Balchem Corp.’s upcoming earnings report date?
Balchem Corp.’s upcoming earnings report date is Apr 24, 2026 which is in 48 days.
How were Balchem Corp.’s earnings last quarter?
Balchem Corp. released its earnings results on Feb 20, 2026. The company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.175 by $0.035.
Is Balchem Corp. overvalued?
According to Wall Street analysts Balchem Corp.’s price is currently Undervalued.
Does Balchem Corp. pay dividends?
Balchem Corp. pays a Annually dividend of $0.96 which represents an annual dividend yield of 0.61%. See more information on Balchem Corp. dividends here
What is Balchem Corp.’s EPS estimate?
Balchem Corp.’s EPS estimate is 1.25.
How many shares outstanding does Balchem Corp. have?
Balchem Corp. has 32,025,390 shares outstanding.
What happened to Balchem Corp.’s price movement after its last earnings report?
Balchem Corp. reported an EPS of $1.21 in its last earnings report, beating expectations of $1.175. Following the earnings report the stock price went down -2.114%.
Which hedge fund is a major shareholder of Balchem Corp.?
Currently, no hedge funds are holding shares in BCPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Balchem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$190.00 (4.02% Upside)
$190.00 (4.02% Upside)
Blogger Sentiment
Bullish
BCPC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 120.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 18.1%
Last 30 Days ▲ 18.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.72%
12-Months-Change
Fundamentals
Return on Equity
12.86%
Trailing 12-Months
Asset Growth
6.39%
Trailing 12-Months
Company Description
Balchem Corp.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.
BCPC Company Deck
BCPC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial tone: Balchem reported multiple record metrics (sales, earnings from operations, adjusted EBITDA, free cash flow), delivered consistent quarter-over-quarter adjusted EBITDA growth, advanced strategic initiatives (international expansion, clinical pipeline, marketing partnerships, microencapsulation facility), and strengthened the balance sheet (lower net debt, repurchases, dividend increase). Challenges noted—higher manufacturing input costs compressing gross margin by ~40 bps, rising operating expenses, regulatory/tariff uncertainty, and remaining work on water reduction—are meaningful but framed as manageable by management through pricing, alternate supply chains, and strategic positioning. Overall, highlights substantially outweigh the lowlights.View all BCPC earnings summariesBCPC Stock 12 Month Forecast
Average Price Target
$190.00
▲(4.02% Upside)
Technical Analysis
Ownership Overview
0.67% Insiders
30.24% Mutual Funds
20.24% Other Institutional Investors
22.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---